内分泌治疗在卵巢癌中的临床获益与死亡风险:综合综述与荟萃分析
该荟萃分析纳入53项试验共2490例晚期上皮性卵巢癌患者,评估内分泌治疗的临床获益率(CBR)和死亡风险。总体汇总CBR为41%(95%CI 0.34-0.48),ER和/或PgR阳性肿瘤为46%,铂敏感肿瘤为55%;6项随机对照试验汇总死亡OR为0.69(95%CI 0.50-0.97),作者认为内分泌治疗活性值得考虑并支持设计良好的随机试验。
要点
- 总体汇总临床获益率为41%(95%CI 0.34-0.48),他莫昔芬43%、芳香化酶抑制剂39%、孕激素37%。
- ER和/或PgR阳性肿瘤汇总CBR为46%(95%CI 0.34-0.57),未知受体肿瘤为37%(95%CI 0.27-0.48)。
- 铂敏感肿瘤汇总CBR为55%(95%CI 0.28-0.80),铂耐药肿瘤为40%(95%CI 0.29-0.51)。
核心结论
- 内分泌治疗在晚期上皮性卵巢癌中具有值得考虑的活性,似乎支持在激素敏感上皮性卵巢癌的一线治疗中开展设计良好的大型随机试验。
研究设计与样本
- 对内分泌药物临床试验的临床获益率和死亡进行荟萃分析,共分析53项试验、2490例患者。
- 按药物类型、ER和PgR状态、铂耐药、治疗线数、肿瘤分级和他莫昔芬剂量计算汇总CBR(SCBR)和死亡OR(SOR)。
- 从9项随机对照试验中的6项计算死亡SOR。
主要发现
- 总体任何内分泌治疗的SCBR为41%(95%CI 0.34-0.48),他莫昔芬为43%(95%CI 0.30-0.56),芳香化酶抑制剂为39%(95%CI 0.29-0.50),孕激素为37%(95%CI 0.26-0.48)。
- ER和/或PgR阳性肿瘤的SCBR为46%(95%CI 0.34-0.57),未知受体肿瘤为37%(95%CI 0.27-0.48)。
- 铂敏感肿瘤的SCBR为55%(95%CI 0.28-0.80),铂耐药肿瘤为40%(95%CI 0.29-0.51)。
- 从9项随机对照试验中的6项计算的死亡SOR显示内分泌治疗降低死亡率(SOR=0.69,95%CI 0.50-0.97),可能在一线治疗和低级别肿瘤中效果更大。
- 随机对照试验的总体质量低。
临床怎么用
- 作者认为内分泌治疗在晚期上皮性卵巢癌中的活性值得考虑,并似乎支持在激素敏感上皮性卵巢癌的一线治疗中开展设计良好的大型随机试验。
局限性
- 随机对照试验的总体质量低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. METHODS: Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose. RESULTS: Fifty-three trials in 2490 patients were analyzed. Overall, SCBR was 41% (95%CI, 0.34-0.48) for any endocrine treatment, 43% (95%CI, 0.30-0.56) for tamoxifen, 39% (95%CI, 0.29-0.50) for aromatase inhibitors and 37% (95%CI, 0.26-0.48) for progestins. The SCBR for ER+ and/or PgR+ tumors was 46% (95%CI, 0.34-0.57) versus 37% (95%CI, 0.27-0.48) in tumors with unknown receptors and 55% in platinum sensitive (95%CI, 0.28-0.80) versus 40% (95%CI, 0.29-0.51) in platinum resistant tumors The SOR for death calculated from 6 out of 9 randomized clinical trials (RCTs) showed a reduced mortality with endocrine therapy (SOR=0.69, 95%CI, 0.50-0.97), with a possible tendency for a greater effect in first line and low grade tumors. The overall quality of the RCTs was low. CONCLUSIONS: The activity of endocrine therapy in advanced EOC is worth considering and seems to support large properly designed randomized trials in the first treatment of hormone sensitive EOC.
引用
- Paleari L, Gandini S, Provinciali N, et al. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. Gynecol Oncol. 2017. PMID: 28705409. doi:10.1016/j.ygyno.2017.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。